{"entity":{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","aka":["ASPRIA"],"tldr":"A phase 2 trial of atezolizumab and sacituzumab govitecan in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting.","summary":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA). ClinicalTrials.gov record last updated 2026-05-04: recruiting. Enrollment is planned at 40 participants. Primary completion is estimated at 2026-12-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Atezolizumab, Sacituzumab govitecan. Registered primary measures: Rate of undetectable circulating tumor cfDNA- 6 Cycles.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04434040","url":"https://clinicaltrials.gov/study/NCT04434040"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":["trop2"],"drugs":["atezolizumab","sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-05-04: recruiting. Enrollment is planned at 40 participants. Primary completion is estimated at 2026-12-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT04434040","phase":"2","setting":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","sponsor":"Dana-Farber Cancer Institute","participation":[{"nct":"NCT04434040","source":"https://clinicaltrials.gov/study/NCT04434040","fetchedAt":"2026-10-07T16:53:19.953Z","studySha256":"4551c03e5bcd2dbe364d039654450b4ab56f9ce97fad5d45efba8366fa4459d6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-04","leadSponsor":"Dana-Farber Cancer Institute","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":7,"recruitingSiteCount":4,"countries":["United States"]}],"started":"2020-07-02","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04434040/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}